Fact-sheet: Retroperitoneal leiomyosarcoma


Updated on 08/25/2026 at 11:32 PM

Note : 10/10 ( 1 note )
Share

View all RADEOS cases associated with this fact-sheet

Definition

Retroperitoneal leiomyosarcoma is a primary malignant neoplasm characterized by smooth muscle differentiation.

Within the retroperitoneal space, it represents the second most common mesenchymal tumor behind liposarcoma, accounting for approximately 11% to 28% of sarcomas in this region.

Understanding its mesodermal origin is fundamental, as it determines its three modes of development:

  • pure extravascular,
  • intravascular (arising from venous walls)
  • or mixed.

Its growth is often expansive and insidious, displacing adjacent structures before invading them at a later stage, making imaging diagnosis crucial for therapeutic planning.

Clinical features

Diagnosis occurs preferentially in the mature adult, with a peak incidence between 54 and 65 years.

A marked female predominance is observed.

Patient profiling should include predisposing genetic factors, screening for:

  • Li-Fraumeni syndrome: germline mutation of the TP53 tumor suppressor gene.
  • Hereditary retinoblastoma: mutation of the RB1 gene (retinoblastoma-cyclin D pathway)
  • In sporadic forms, complex genomic alterations are the rule, including biallelic TP53 inactivation in nearly 50% of cases.

Clinical presentation is often delayed due to the compliance of the retroperitoneal space: palpable mass, compressive pain, or abdominal distension.

On a biological level, conventional serum tumor markers are generally noncontributory, unlike in germ cell tumors or adenocarcinomas.

When the tumor arises from or invades the IVC (approximately 38% of cases), the clinical semiology is dictated by the affected segment:

  • Segment 1 (infrarenal): lower limb edema and collateral venous circulation (varicose veins).
  • Segment 2 (retrohepatic/interrenohepatic): the most commonly affected segment (43% to 69%). It may lead to renal venous hypertension and renal dysfunction.
  • Segment 3 (suprahepatic): the rarest location (6% to 20%), capable of triggering Budd-Chiari syndrome (hepatomegaly, jaundice, ascites).

Ultrasound

Lobulated, solid mass, iso- or hyperechoic relative to the hepatic parenchyma.

Areas of necrosis appear as irregular anechoic or hypoechoic zones.

Color Doppler is essential to identify intralesional vascular flow, indicating the tumoral nature of an endovascular thrombus.

CT

Contrast-enhanced CT is the reference examination for preoperative planning.

Three phenotypes:

  • Extravascular form (62%): Bulky mass often occupying the perirenal or posterior pararenal spaces. Enhancement is typically heterogeneous, predominating at the periphery of the lesion.
  • Mixed form (33%): Simultaneous endo- and exovascular components.
  • Intravascular form (5%): Dilation of the IVC or renal veins by a soft-tissue mass with heterogeneous enhancement.

Indirect sign (present in 61% of cases): visualization of collateral circulation (azygos system, lumbar veins) reflecting the chronicity of venous obstruction.

Staging workup seeking metastasis to lung (65%), liver (53%), and then retroperitoneal disease.

MRI

MRI is superior for assessing local extension and tissue characterization.

  • Signal: The solid component is iso- to hypointense on T1 and hyperintense on T2. Necrosis appears markedly hyperintense on T2. In cases of hemorrhagic change, spontaneous T1 hyperintensity may be observed.
  • Diffusion sequences: Marked restriction (low ADC) correlating with high cellularity.
  • "Black-blood" sequences: Essential for delineating intravascular extension, they provide optimal contrast between the signal void of blood flow and the intermediate signal of the tumor.
  • Differential diagnosis of thrombus: Enhancement after Gadolinium injection is the discriminating criterion for distinguishing tumor thrombus (vascularized) from bland thrombus (non-enhancing), the latter potentially coexisting downstream of the tumoral obstruction.

Vascular intervention

Coaxial biopsy for pathological analysis: Performed under CT or ultrasound guidance, for diagnostic confirmation and prior to neoadjuvant treatment.

Nuclear medicine

18-FDG PET-CT: Effective initial staging tool and reference examination for early detection of local recurrence and distant metastases.

Management

Management should be centralized at an expert center.

Goal = R0 surgical resection, often requiring sacrifice of adjacent organs (kidney, adrenal gland, pancreas) or complex vascular reconstructions.

Chest-abdomen-pelvis CT +/- surveillance MRI according to the following schedule:

  • Every 3 to 6 months for 2 to 3 years.
  • Then every 6 months for 2 years.
  • Then annual surveillance.

Classification

T Staging

  • T1 <5cm
  • T2: 5-10cm
  • T3: 10-15cm
  • T4: >15cm

Prognostic Stages

  • Stage IA: T1, Grade 1, N0, M0.
  • Stage IB: T2 to T4, Grade 1, N0, M0.
  • Stage II: T1, Grade 2 or 3, N0, M0.
  • Stage IIIA: T2, Grade 2 or 3, N0, M0.
  • Stage IIIB: T3 or T4, Grade 2 or 3, N0, M0 OR any T with nodal involvement (N1).
  • Stage IV: Presence of distant metastases (M1).

Differential diagnosis

  • Retroperitoneal liposarcoma: Constant presence of macroscopic fat (density < -20 HU); calcifications more frequent (30%).
  • Lymphoma: Homogeneous mass encasing the vessels without invading them, with the characteristic sign of the aorta lifted off the spine. No necrosis prior to treatment.
  • Schwannoma: Paraspinal or presacral location. "Target" sign on MRI (T2 hypointense center, T2 hyperintense periphery).
  • Paraganglioma: Early and intense ("flash") enhancement. Predilection for the organ of Zuckerkandl (origin of the inferior mesenteric artery).
  • Castleman disease: Intense and early enhancement, frequent calcifications, and presence of small satellite nodules.
  • Hematoma: Complete absence of enhancement, intrinsic T1 hyperintense signal, and T2 hypointense hemosiderin rim.
  • Retroperitoneal fibrosis: Soft-tissue plaque centered on L4 surrounding the aorta and iliac vessels, causing no aortic displacement but medial deviation of the ureters.